β¬23.83-0.06 (-0.25%)
Koninklijke Philips N.V.
Koninklijke Philips N.V. in the Healthcare sector is trading at β¬23.83 with a market capitalization of $21.9B. Wall Street consensus targets β¬27.93 (20 analysts), implying a +17.2% move over the next 12 months. The stock is currently 14% below its 52-week high of β¬27.70, remaining 2.5% above its 200-day moving average. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (EUR) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | β¬4.10Bβ | β¬4.34Bβ | β¬4.30Bβ | β¬5.10Bβ | β¬3.90B |
| Gross Profit | β¬1.85Bβ | β¬2.01Bβ | β¬1.91Bβ | β¬2.29Bβ | β¬1.77B |
| Operating Income | β¬155.00Mβ | β¬401.00Mβ | β¬330.00Mβ | β¬565.00Mβ | β¬242.00M |
| Net Income | β¬76.00Mβ | β¬240.00Mβ | β¬184.00Mβ | β¬395.00Mβ | β¬151.00M |
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imagin...
The Walt Disney Company (NYSE:DIS) is one of the safe stocks for beginners to buy in 2026. The Walt Disney Company (NYSE:DIS) and Omnicom announced on June 23 a new collaboration between Omnicom Media and Disney Advertising to implement a connected TV ad solution enabling dynamic sequential storytelling across both video on demand and live [β¦]
European equities traded in the US as American depositary receipts rose late Thursday morning with t
Domino's named chief operating officer and US president Joe Jordan as its next CEO. The stock is down 30% year to date.
Semiconductors are the picks and shovels of modern technology. The way we live and work is also changing with AI, which is creating secular demand for more powerful chips. As a result, the industry has seen solid stock price performance over the last six months as its gain of 125% has outpaced the S&P 500βs 8.9% return.
Shares of medical device company ResMed (NYSE:RMD) fell 4.5% in the afternoon session after Morgan Stanley downgraded the stock to Equalweight from Overweight and lowered its price target.